Insulet (PODD) 8 Aug 242024 Q2 Earnings call transcript

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference call is being recorded.

And I would now like to turn the conference over to your host, Deborah Gordon, Vice President Investor Relations.

Good afternoon, and thank you for joining us for Insulet's Second Quarter 2024 Earnings Call.

With me today are Jim Hollingshead, President and Chief Executive Officer; and Ana Maria Chadwick, Chief Financial Officer and Treasurer.

of this results the be and the Relations of our release available replay Investor quarter second XXXX section the call press and discussing on Both website. our guidance will website our earnings our Also on is presentation. supplemental for We key summary metrics encourage of updates. a that business you reference to document and

statements that to we from of our forward-looking by and the in materially statements differ Insulet the call during a we begin, of certain this be Before the expectations. such may refer Please current cautionary remind you for explanation filings made course of SEC statements. could detailed limitations inherent

We'll measures for and respect to constant with with they as uses align also of in growth to EBITDA which believe are revenue, namely helpful effect is what well. revenue our period management as adjusted financial from discuss measures operating currency performance non-GAAP supplemental period, excluding These our assessing we exchange. measures and others the performance, foreign

financial be regarding and revenue year-over-year the Additionally, unless reported rates, a commentary with currency basis. dollar constant will a otherwise will percentage which be exception growth basis of year-over-year on on all stated, changes

to With call that, over Jim. I'll the turn

us. Thanks, thank Deb. and for you Good joining afternoon,

growth, XXXX of and be year is fueled Omnipod innovation. another shaping for by our of up demand product rapid strong pace to X accelerating

improve the increasing markets, even of expansion results is deliver level lives we revenue of with and leader reinforce our half advancing growth Our and industry team our and U.S. and mission strong another a demonstrate velocity, in high both to people the significant strategic year first delivery. The and we robust results clear financial delivering half, of our our continue our simplify an insulin in confidence in second These diabetes. to all stronger the on margin remain QX internationally, as performance initiatives. momentum at financial strong execution with in across and executing Insulet and automated and

QX guidance gross expectations things: margin. and today's the of and we revenue, for across first our revenue of quarter year X our against globally, three board. our the to strength call, value half you XXXX light results, execution operating expand in momentum, margin platform capturing market; our on strong the full continued exceeded Second Omnipod update In our the I'll ongoing On across objectives increased and results our competitive the of success and continuing position business. lastly, scale

growth technology to and maintained of with of Starting performance. growth customer achieved landscape. of achieving diabetes In sequential with momentum growth growth financial line total in expectations. in revenue in QX, disrupt the including the international U.S., our In QX, starts, continues new X Omnipod XX% U.S. strong we we Omnipod XX%, XX%. a

drive injections therapy. is out expansion Omnipod market bringing to Our multiple onto through focus strategy on people daily of our

As a rapidly overall expansion. focus, result base our customer the of while increase to we remaining of at driving market continue that forefront

growth Our driven by diabetes. new X was type users and MDI type from both increasing in customer starts in X the quarter

at manufacturers have level, switching market which lower dynamic a technology in At are a emerging pump we customers an who adopted rate. seeing are

As dynamic business. our customer part MDI, market our result from a starts in continuing switches smaller of become of and leadership that a have our competitive new

more customers we switching, be winner to competitive lose. However, net continue in the winning we than

with turn scope The helped and clear and scale came in and to share paying to the this we to type continue for and both During physician the maintain people simplicity, pharmacy new benefit has channel. in competitive growing within endocrinologists are which people from X populations, hard writing our using the continue our this number channel built among access prescribers competitors. Across We're have of type from significantly the take platform with U.S. channels. Insulet is prior customer we type advantage primary also the care X increased choice the and roughly XX% we starts quarter, the starts increase type working quarter, from new and our both previously work very X customer consistent practitioners MDI, off. and in also X. of and care drive leader health is for remains retention. customer Omnipod high clear A awareness strong scripts to our Omnipod in

we to excited again the year. revenue will receive expectations. this X, type international were clearance customer it we for goes. label detail subject We deliver In expansion, wins opportunity moments. Omnipod about Omnipod a in FDA ahead new more starts growth us to I pleased of everywhere in QX, provide which are hope X for our few X huge to and

are a result time of outlook, our XXX basis raising success, significantly by we this revenue this international As points.

end as $X.X with been X X are XXXX, results early at rapidly markets approaching returns annual international billion country the these The more revenue launches the revenue we achieving to we're and achieve for growth of We're outlook. significant to international to just to accelerated our and high in in access expand for We've innings. continued we growth rates XX% still the serve. X only Omnipod signals of which above us we all started, international getting able runway full us in

launching year, of would we multiple we that And that, cascade we expansions. deliver to QX, a do continued just innovation. this promised platform Earlier in XXXX, in

adoption of release, growth we GX U.S. Full integration GX Dexcom's latest market successful both more GX the offer and us weeks of entered allows X with in our full Following even customers Dexcom's capture Omnipod our release the of with choice for quarter. to sensor. the last limited and X and

pharmacies. X GX customers packs has through new ensure GX deliver outstanding This is reminder, us Omnipod to their an that and specialty a customer X experience seamlessly. exclusively now and several with allowed receive Pod available As starter Omnipod

and GX strong. our expectations. with is line Demand results Early promising offering our for are in

on us starts increases year. during half customers to in demand. with We which we is pleased the provide term, operating in ongoing this to customer continue with new can us near it and inventory at the the a tailwind meet allows performance second have we been of our expect will It focus channel. the in new of And scale, flex to

Last week, Omnipod and in over-the-air to customers provided a smartphones pair to able preferred controllers retail once compatible GX. they their update free will we to be GX customers existing compatible Existing appear move X their enabling with our Pods see pharmacy. software

of a launch. channel and in partners, will gross the on Given potential pharmacy pace. shift specialty impact any of allow natural while progress potential success the This us risk product more also and returns minimizing our inventory to decision our to outlets the our our recently allow We at customers, retail to minimize for confusion potential margins. made the

naturally We usual of more tailwind an additional now will expect new planned QX. resell ease continue to the starts in GX pharmacy Pods customer as widely available, become later as provide

market X QX, the GX, limited During achieved we major very app and is launch U.S. well. another our Omnipod iOS with of with progressing milestone the release initial

ability in continue it Podder fall. the that's is gratifying gives We a managing Podder iPhone having It a our diabetes then our "Omnipod the are with to hear and had early also users since transition the is biggest hearing introduction on scaling release confidence the is. just background." in the tell limited feedback of this us innovation to from shared We "Omnipod device." how experience delightful that, one system full in It's release the everything and X, One "liberating" AID. more even us, X, to

the of we X this end in cascade are to Plus that FreeStyle U.S., integrated launch by of innovation to pleased this X the Omnipod sensor we Libre Adding to announce Abbott's expect year. with

who have We are are Omnipod generate as excited in of to expand to of in we sensors, the the chosen launches portfolio Libre early family Omnipod seeing days and the are X this we expansion offering will X, internationally. our X our with reach Plus confident Libre demand for just U.S. increased customers

into Libre QX, to U.K. with the Turning Omnipod Netherlands. Plus and extended first offer Abbott's to sensor the also this Plus integration In in introducing platform sensor international. Pod markets which integrated both we This new marked choice the offering, offering were X compatible X and is we our first Libre GX. and of with internationally, X

experience, either Omnipod are HCPs patients from integrations an is that We how to hearing using outstanding including providing sensor. are it start X leading and both easy

recently global our in X one Further largest reach, launched Omnipod of markets. France, which is we expanding

drive days been high positive France. strength continue clinical launch feedback always very We we noted from are has emphasis in outcomes have as expect and the patients other early Omnipod in adoption to HCPs we HCPs robust on Omnipod international with the X, to have seen our and build successfully X's particular on in and markets. And for has fantastic. this Omnipod been Demand with simplicity.

customers. to Omnipod the X majority not are of And we available European stopping course, there. is our now of

to with for stages in Switzerland planning Nordics, follow. final We the Belgium, are in soon Australia, and the launches Italy, additional Canada, others

local all to work our our the you near-term market prepare in XXXX. begin pipeline, launches for of planned throughout For countries commercial see will us

keep are will the on our opportunity progress, updated We we enormous pursuing. on international capitalizing you

to opportunity business. represents growth our X Turning type which another in diabetes, for significant

significantly the trend. our type our the The delivery large is starts, therapy XX% roughly X insulin type type is intensive the population. ongoing second with in market of continuing represented already are strong people leader We the In space. a roughly U.S. quarter, customer patient size The basal and X insulin using or of underpenetrated. either market Xx combined insulin, X population new

commercial pathways for and the type innovation have space, we important This clinical. year, X both had in two

our know, to optimal of a has in you users. practices patient we purpose determine patient develop can the a main two, pilot so have product needs identifying expand to our led at designing the The aimed pilot better profiles been we needs. of understanding has As patient that strategy. accomplish of presents our two better GO, Omnipod basal-only and piloting profile one, multiple goals: commercially and to insulin force; sales serve way that nonspecialist go-to-market This the been

called I ADA, a pursuing our clinical we the the expand X topline to trial with work for SECURE-TXD. with want pivotal take of been meaningfully our parallel, to type diabetes, at to moment X In presented recently have results. with trial Omnipod most and summarize key people data We offerings some

ever relevant because U.S. largest of in patients view of SECURE-TXD they results diabetes, and in delivery the will highly be point for both the important completing the XXX study the participants of general as This were X diverse insulin clinically present is population people the representative real from and study to study approximately the the automated protocol. health use equity the in type world. with is completed The of

average were Omnipod delivered an with greater reduction outcomes study of results were notably, or X.X. And across GLP-X not an More average cohorts, Those a the on therapy. higher. X reduction baseline population the clinical the achieved increasing the than AXc AXc were The AXcs of participants striking. baseline X.X whether with half than of X GLP-X. AXc across concurrently same as on on were all benefit

is Importantly, key this was injections, study to basal-only were participants also line with on roughly risk hypoglycemia. SECURE-TXD, population, of benefited users. barrier XX% in insulin intensive in a adoption currently the in there insulin and In increase hypoglycemia. insulin of no And they

valid other clinically diabetes. distress. demonstrate X in benefit remarkable Finally, a study benefits, with X's people and reported demonstrated meaningful Omnipod among type reduction clearly several participants results diabetes for These

of basis expansion indications the for the results, these X On FDA. with Omnipod use of for in for we filed June, our

our will in work expansion, our X. on we our currently In learnings and that innovation FDA coming our from results of X efforts of on investments Omnipod make force to anticipation the label sales our focus strong commercial streams quarters, extend two further successful Omnipod such sales penetrate street targeted together. from expand feet pilot, during our GO we model our these the base, and to Now Omnipod prescribing will the we trial the clinical clearance rich and will have come

a therapy. of insulin believe on replace both insulin. strongly X We those X as Therefore, benefit type to will Omnipod X those wide for with using will provide Omnipod people insulin diabetes using Omnipod MDI GO X and patients, type range offering our basal-only basal-only on

therapies. and and them that pilot we transition forward in other their the are HCPs participated for We to our the grateful supporting to look in Omnipod patients

management to this chain manufacturing, supply separate in existing by for serve need streamlining platform. ongoing a X enable Omnipod space product in operations, leveraging and investments for will product with it eliminates Leading more cycle us customers life the and and

in More X confident importantly, type we win clear have are to right space. a we the

product the market be to not Omnipod platform AID launched type AID offering, in X the with which into it an in and X. offering, to quickly X, expect leapfrogged any once but leadership market just with is we type We that first

upfront to simplicity a already of Omnipod unique market-leading disposable the cost, both control convenience of patch full pharmacy access to phone and the patients with X the discretion pump benefits iOS. type wearable, ease channel, will low the of and bring day-to-day with and to no X that use ease all Android it delivers, of

clinical established All have benefits while trial. of that, pivotal just the we striking delivering with our

financial We market are excited have pending delivery clearance by impact insulin a addressable by more financial offer to our of FDA. end the the us fully on will refined moments, of the growth. our new strategy bring type few the detail automated fuel to impact we of but a the best opening will will Ana market expect year, the biggest the which in this be X for

we new made over the manufacturing scale in which and innovation I'd our discuss like have faster meaningfully expand cash I to Ana, Before capabilities. state-of-the-art us And investment our been Malaysia, to in facility, is and expanded successfully enable margin Acton flow. will investing briefly plant in hand We've significant which manufacturing margins to contributing expansion. global gross process in to

to are Omnipod begun ahead schedule. have product in in thrilled X We sellable producing Malaysia of QX

Our Xx new over year ramping our facility increase. of volumes the facility, gross first is to and be to its expect production, accretive we in full U.S. margin it of as size

position profitably business grow an scale X, seamlessly over meet and global us Omnipod our and and for the advantage growing advantages competitors. Our important to which distinct demand represents

who as Insulet make members as executive look travel team other this after this this with several globally helped our to employees many our to grand team happen. call, facility's opening. to local of celebrating official Malaysia Shortly occasion attend forward We well our the will

that, With to and call our guidance. turn walk through results over I'll Ana to you the

you, good Thank Jim, everyone. and afternoon,

Most team our with continues our of significant mission another have momentum advance execution. strong to importantly, delivered improve people financial to of diabetes. and throughout We global lives and business the and quarter our global simplify results strategic

of expectations. our growth, exceeded XX% by XX%. total results driven growth quarter achieved Second revenue We Omnipod

integrated points currency was is retention end reported X was approximately our of Omnipod the growth, our basis XX%, revenue finishing with the The global guidance. while above our U.S. with integration GX Omnipod our stable. of GX XX total favorable revenue driver company is remained estimated Our on basis foreign reported gaining a high range. momentum. strong guidance primary impact on growth versus

channel months. few dynamic this We are more our U.S. over market we launched will continue the partners speak excited will to full into June, GX in with coming and release have face I our a moments. to to in

manage offset our U.S. Our on and success channel, revenue million growth was our Pod. increasing estimated reduction customer $XX was driven the expanding our in volume base channel by year-over-year primarily an pharmacy of partially the throughout premium including by the with This first to GX inventory were was slightly Omnipod ramp year XXXX. as trends the expectations. U.S. we X in X's line in significant in GX the of prior transition, result utilization a than Omnipod our full launch as year which of lower

due expectations, revenue to guidance of end was execution. it our high to we half the U.S. our estimate versus of our commercial beat our relates As approximately strong

as GX The due than pricing Pod to mix channel well as anticipated. returns benefits fewer was other from half

strong. is growth underlying Our

and We well revenue have our the have are position greater robust great to to expanded many and this product offering provide customers. growth XXXX choice momentum, a beyond. thrilled for position base for and we the to in in in significant and year, deliver are us our customer With lead and market our catalysts continue we

results Turning were achieved our international revenue XX%. growth once to above Omnipod expectations. of international. We well These again

the high and DASH of doing our are growth. Last X's is remains overall start both year's sizable volume, our growth. new launch and fueling driving very customer Omnipod demand revenue and well Germany and While is a in U.K. international internationally Omnipod very percentage

around in Omnipod Plus our demand France seeing with XQ, Omnipod recent we're of continued two positioned increased our launch of Together very for Although result X is a as well markets encouraging. rollout early, are start of in of with the X Libre the growth. we our

was points over Omnipod X to smaller currency International U.S., markets, and was were points expected well utilized. our our year from and but higher to due degree. above strategic of in that our basis This our this continue or in throughout not reported Even initial XX.X%, orders, components with to go partner trends resulted drive what Omnipod prior delivery decision year efficiently. to we business XX to of utilization which was million guide. both an market versus the year of charge foreign manufacturing points, we GO the approximately similar basis XXX offsetting our saw pharmacy Omnipod to revenue this a X as increase our over On as significant long headwind points basis a in to higher as to in which partially XXX U.S. channel term are trajectory was in primarily execute production. Gross charge type strengthens driven and than prior efficiencies. basis, FDA expansion, timing last scale margin clearance. by up million, basis due our $XX.X instead charge, ongoing $X favorable a to international slightly Drug range, relating in onetime orders pending was guidance our growth X margin XX with global pricing and in execution confidence our benefits from to be the Partially the accelerated growth resulting is margin

business. outperformance our At and we our time, revenue, of second In leverage been from to operational EBITDA resulting margin year. in invest gross shift both offset of support shift XX.X% realizing revenue While continue we due of we spend. come, are our have improvements was into was innovations our by of timing we expectations, margin operating spend $XX.X million was order drive those the the in metrics of our as half Omnipod to level Expansion increased growth business, XX.X% are we've to performance, revenue cascade above-market or points in due operating of expansion and the and delivering, had and GO. XXX basis related the in expenses we timing partially the the adjusted to onetime including to to the quarter than of business. Operating year a lower margin to achieving invest the our these was we the will throughout charge this primarily our expected exceeding same

reached to may had due our we allowance our required. provided we tax in longer year Last the assets be color point against the quarter, that positive at valuation may that trend, earnings some we In majority deferred find no this approximately we allowance, the resulting our in QX, $XXX million benefit period, tax therefore, conclusion, out of for released the in and which adjusted we we purposes. of non-GAAP a valuation noncash

$XX be rate, effective XX%. the the excluding now XXXX during another We expect of $XXX our expect the to year. recognized million full to We the of be tax million to in XX% range remainder

cash credit extended loan interest ended our August $XXX to interest the and and over with full cash of to expense loan liquidity. available rate, by loan under approximately the which in repriced quarter Turning $XXX cumulative at of will facility. lower We the maturity $XX reduce million. and week, term B the Last a the we successfully million XXXX the term approximately million our

cash and resulting our to drive commitment ability is Our free our paying expand and overall profitable positive profile. strengthen in financial off, margins to growth flow

Now XXXX turning outlook. our to

milestone total expectations a range. billion high of are to year, growth revenue in our representing XX%, Omnipod full the our of we of again to For for range end $X a annual raising at the once revenue XX%

of XX%. As company to revenue a raising also growth to we total a are XX% range result,

Omnipod, to of low XX% a our For guidance now end and revenue XX% growth. expect of raising U.S. range we're the

X, our customer by of continued We the be benefits demand revenue strong from growing to and expect for the Omnipod annuity base. growth stream model primarily including reoccurring driven

orders a from As of we the comparison estimated quarter XXXX. versus prior year tougher resulting that a XXXX in of accelerated in XXXX have reminder, second the period the from were fourth half the

revenue continue higher starts be XXXX dollars the half. customer half anticipate levels second to and first new to in both in We than of the

less both customer our and starts While to, new in in guidance that the retail Pods GX Jim steep customer sequential half QX we new by reduction in driven QX, channel of longer both our continue our second ramp partners. now competitive of in period and of through facing switching to starts the contemplates expect overall slightly referred XXXX, a growth market the

a impact temporary new While the on it second is half, timing. simply the starts latter customer during has

benefit Pod the We GX this of while maximize are is the of returns top confident added and channel. customer will HCP our strategy which priority, experience, having in limiting the the

in continues Pods throughout expand our Our assume this second of all we channel revenue restocking as partners. guidance distribution half gradual to the year of a GX our

basis Germany, be impact. driven launches anticipate revenue our to we by international will growth For points we headwinds expectations by Omnipod, revenue Omnipod strong reported foreign last Omnipod a X. range yet there of XXX to the to be XX% not We On do the are growth offset basis, year's no have in from momentum X partially where we a now raising XX%. and assume by U.K. countries in currency

international XXXX the raising strengthened clearly Our achieving we has been X resulted day advanced Greater-than-expected traction Omnipod customer taking we as are revenue Omnipod Feedback share. international of and our since start X. business by technology. has for points with outperformance, new by and a is tremendous, every today, as are in basis the starts with outlook well Omnipod success our gaining outlook X,XXX is XXXX. leader

second new we our half to contribute expect annuity of given of we most even contribute Omnipod nature model, X expect XXXX. recent this more While to in the starts the launches customer in to meaningfully year, revenue to our them

launch. that Our our internationally every strengthens further confidence in in incredible gain share which X market Omnipod will growth momentum drive we and

guidance inventory for Omnipod, in This channel product from levels generations. launches XXXX. prior and have in fluctuations the resulting we quarterly the International ramping revenue and Omnipod launches many U.S. our factors reducing both in new For of includes

our in decline drug to partner's for expect Lastly, we our revised of delivered, has the outlook XX% a reflecting forecast. range XX%, improved now and

gross XXXX to margin. Turning

the the risks first and in manufacturing modeled full of launches our outlook. XXXX and to have year our some half new facility, of had performance related margin we strong confidence product XXXX greater we retirement in our Given

result, a end quarter second land As the GO to Omnipod high annualized XX the with impact basis we even the to now our XX% to charge. XX% points of closer from range, expect

in to we term, are tremendous deliver long and remain strategy and to the We a further committed executing over this near drive position expansion margin gross our to growth.

We remain to growth driving margin on efficiencies we expansion even committed and of and as fuel commercial, to our we as heavily clinical in R&D scale, to operating invest capitalize continue economies revenue trajectory. our strong

a margin are another As we to result, points once raising XX%. basis guidance XX again operating approximately

our third Turning guidance. to quarter

expect XX% of of We company XX%. to XX% to growth total total Omnipod and growth XX%

for For X, growth demand XX%, by of benefit XX% driven the primarily U.S. to of customer starts our strong and model. expect Omnipod, stronger annuity we Omnipod

expect currency XX% assume unfavorable by we X, reported of in Omnipod countries now ongoing Omnipod basis, partially of a Omnipod, where On to XX%, of by points. growth X. For an have offset driven basis foreign do International impact headwinds not we adoption we XXX yet

revenue drug QX to $X expect million. $X be we approximately Finally, delivery million to

generated of and our revenue expansion new starts the please position conclusion, for continues to this strengthens and We Insulet year In robust to results. operator, customer growth beyond. With team and and deliver questions. strong sustained drive that, margin globally execute innovation our our global call open cascade

the JPMorgan. from line first your And comes question Robbie Marcus with Instructions] of [Operator

in. all Congrats a want I really to ask them quarter. questions some get just on here. nice clarifying I'll

what back have onetime down it something backed without margin out. would write the EBITDA reason higher was operating materially would it have and XX.X% it to charge been margin the to out? been the have inventory. not think in and leave to I companies First, most closer I gross would guess,

around in the year-over-year? just patients a new second Is commentary X I add it patient ramp just little Just second, commentary little could Is Maybe confusion view crystal clear it to less the a to grow it the patients? new then can make specifically? half. you it there's and you switches? related Is type new And competitive on think the that? clarifying

and on margin to call. I'll have thanks you the the Ana Thanks, onetime your Robbie. the for back start great customer Thanks charge. the then hand for your It's about and start talk to new I'll question, question, to on congrats. and

customer to is we And see sequential really, clearly. new trying our was thing along we starts first had So the good the those starts, and in which what new really customer increase we're describe our hit market we in guides. goal

the we're in trying market, we've seeing we're to the trend market. characterize the seen in What

down. as looking we was we've quarters. the data, clear just of there over that So MDI couple just some question and type looked total we what just in X what it's were dynamic at base of both already last installed that the in where to can and But think And we down. is type is in for looking a is the competitive up was seasonality patients extent to And that in X. the installed base the I see switching market-wide, quarter, see back, pool competitive the switchers

for that of grown really several is And of we've last over one that, our base course, percentage the reasons of the substantially. the installed quarters,

X of smaller a us of market users the users on part it's of it's targets for a that market. not lot it's Omnipod are a switch. part -- out the and part smaller Omnipod are out there there that So of But to there, market what's going overall, in mostly the

The trying the for important convey is thing is MDI. us, that, to that we're play

of X between new for start out out it, MDI switching competitive of are our if XX comes think or So us. X coming you customer X of new only about from starts and about somewhere customer

clearly do. our MDI. Having we're what we and very strategy. We're in win clear. to lose. as But see win That's market. the also we're that's in to market, is for of the in to and trying continue the leading so all very, overall so continue to happening That's Omnipod trend you we appealing. that, the clearly X And player we're growing more said lead customers we switching We what we than trying characterize competitive an game. that's

will consistent that, to play overall bring lead because Our and more X the continue to strategy. we to in, allows market grow with very clearly patients in Omnipod be us our

on up pick margin that to want you do Ana, question?

Sure.

So for absolutely, Jim, thank that. you,

not script year, we XXX and all during background the tried earnings margin quarter basis and The operational takes for the and full to points. we do press for puts adjust is we points for to of the XX the up But what here in give you the margin our basis the items. gross from do through flows release, that

adjusting see can we're one-timer, you well. So that incredibly we're executing

question the Johnson next line Jeff of with your And comes Baird. from

maybe on store question have on one question do can new the your I I then Jim, other And ask implied guidance. one quarter clarifying comments fourth

MDI new heard or kind up of I quarter. saying final On sure of And combined, had overall that your make or sequentially, is confirm everything a is it just what number fourth think U.S., then want starts plus U.S. globally on like new the lot I the I put I to that the to that? and you that global the up said, starts, either I new that the a and starts company you were question competitive convert, on were

Yes.

So yes, so for Jeff, question. the thank you

to U.S. clear. internationally New just both in starts were the be sequentially and up, sequentially,

the point in from digits, there XQ your within Omnipod pick where because implied double what or at taking growth I to Omnipod the pick bigger a U.S. to then just on the on probably fourth single helpful. estimate implied the midpoint we're point When Ana either on quarter for you, XQ. digits U.S. range Jim. guidance, That's guidance, quarter Okay. the And for guidance, fourth low decided I look is or low depending -- I the

fourth hopper, U.S. last you're You that count X Omnipod depending talking to that's on points forward into year-over-year obviously year I the X much seems in headwind. pull kind about the how of all the low from When put to a we growth it quarter in like of mid-teens. kind had XQ 'XX anywhere

about XXXX, to above growth? One, low is point of we XXXX? thinking you're is that, type mid-teens that about where growth? adjusted Or kind there off be other can think way is that reasonable like a that for how maybe you in and that Omnipod should things U.S. X stepping about to Omnipod U.S. And as a thinking take

the that. Thanks start with question. I'll Jeff, for

quarter. in especially fourth a You are of are absolutely correct. There and absolutely puts lot the takes,

our here guidance with I that you're that guidance high year U.S. overall for to specific that of is end The referring continues know important at be the thing to to recall our the strong, here and XX%.

we do providing the XX% this wrap to at I during mention something want we We'll the up until the raised fourth which are we wait think to XXXX, of guidance as up XX%. call. volume we not So quarter.

We transpiring lot we things of year, have second iOS. as a the in GX, half the of Jim here, mentioned have

have We Plus. X Libre

later part ramping have ahead the We and we'll back we guidance. international countries and really more type come year, nicely additional X clarity have Once into we that that provide extension. of the label more have and the the incredibly is

your from Larry next question And comes the with of Fargo. Biegelsen line Wells

U.S. -- one Did new overall QX? starts new on QX to me. clarification you and say starts starts up Jim, for be in

Yes.

clarifying to going we're I clearly. a let characterize give So Larry, can know see it it lot I'll questions I another get I'll just -- actually of this. on if try. me

stronger X, big be the sequentially GX with ramp half again then in for remain course customer course starts the have same. second in So we in to consistent X U.S. sequential last and we is the quarters, the us X, the the we year. driver what tailwinds where tailwind QX in said expect we've the and -- over of QX, X new And expect stronger The other X, then and QX. characteristics that's growth over coming. the And of X

two experience a win I is said And clearly asking the that the think good. as GX we to market experience there's well have One to in through really We're that changed because sure good. as in Demand inventory in we people of there's customer made well. specialty prepared overall quarter. is our channel. comments, And that not are things thing is, that let is does switching. we launch of competitive in pharmacy is, although where and more we one it smaller continue other flow into ramp is switching, going question channel themselves is terms the said, portion competitive servicing and the I'm mean that the what the land. I the the channel to naturally of disrupt that But decision very the is

the half. bit would outlook second a things change in And a both our say, little starts new in of I bit, so customer total little a those on create of

second And her ramp steep probably the is been half as a in we less expecting little but comments, had we the so Ana ramp, characterized in expect before. steep bit a than

them total ramp in second But customer in that in new terms characterize. a the but kind second is dynamics what to really the lands starts to where year less Each of half, a of U.S. Now X the in quantify those good is steep customer expecting hard starts is of hard new combined, neither still each those -- of ramp we're that of half in are big.

Okay.

So Jim.

so If the about one-time wanted your in the ask quarter, was think, in keeping XX%. margins, second margin even charge about the that's The with about. the I implied in, gross I And out half, onetime to first take it's charge what XX.X%. -- I

from half? your the think benefit lower the margin in margin underlying gross the -- how why lower gross And about second we So beyond first to the Malaysia versus half XXXX? should

Yes.

me Let that. jump into

So had we and XX.X%. margin have first now quarter, in gross we XX.X%, of the

So the And guiding be, XX%. us as the we expect can gets that to XX%. full the imagine, second of you we're to shy half, in

higher XX% the be than going that's So to overall. to make the

from Omnipod So contemplates that that We the want full in back quarter did the took XX contemplates just year points -- this guidance. guidance, kept XX charge clear, be I basis our that we for that pressure. our that guidance. out not We GO of to

the answer that helps So question. hopefully,

more has impact. limited a Malaysia

running So benefit and into year as of as XXXX to to that more it's first produce the move starting we full we get operations. and product, expect of

And your Kaczor of line from William next question Blair. comes Margaret with the

having and and on of obviously, international on amount one a one in the you're guess tremendous But apologies both U.S., I internationally, seeing here. for traction.

So countries in? U.S. similar can can change U.S. converts, is the I'm are is a sure you the And Are new taking you more X you But then this the as converts. may isn't This general, where side, give in related competitive are a ago? And quarter in on get you how we're X this us countries, this starts patient just the this and switches much me is just MDI of a hey, just, sense the patient is guidance seeing kind adds, or patient these start may new in not. to to trend. that to to what's which change say, it. adds market be historically, the new XX% competitive of happening new of hey, sense ground? some a competitive just clarification But range helpful, around of question that on in adds, years trying of few going we in part saw is on it beaten

Now you're saying XX%. it's

I'm So the seems correct but on pretty minor, delta wrong if me X%, that.

international, take to to wins of extremely The pleased perform I'll continue is Thanks, internationally. Omnipod Margaret. a launch take ahead -- off both well we previous those. we're countries go clearly Germany U.K. strong of Yes. X of It performance The On with continues both so extremely expectation. it. to well. and quarters, launch we're going able in wherever very those

have for early. and very It's know France France. in big but launched just out. demand, us, really we big rolling we we're that We've market a is

product with our other going of on of the on where Netherlands, and that Sensor we we that of And market that's we is the GX, ramp. that was Netherlands. into great. that is, offering, offering Choice country, our and patients offering U.K., when took beginning is when the Choice and have then Sensor launch GX to We And which were it entered entered with launched course, first we -- Libre already the X, and

driven those largely are these growth all MDI of growth -- phenomenon countries. So in

internationally, on locked technology people their are contracts. into As most you are know, who

paves us, really X road largely MDI on makes them we pumpers, a they're And bullish and as for already are to continue it performance, so new-to-market really, very it's Omnipod the CGM out but pleased of roll Many with largely we're new-to-market and customers. a CGM us because internationally.

I what dynamic, what's market, you're a U.S. bit right, that focus. at of yes, there's going percentage a consistent we're odd. as It's base what is switching there now look had not shift mix characterize mix business. we of the competitive is shift. know But -- last our the smaller. questions see of just of trying our We market. That's never It's the mean the It's little On kind out been there. lots on we It's out But with in quarter, focus we smaller part where XX-XX. to trend is about it. the a total

up U.S., But a X is clearly big lead not up to split market that in focus We MDI dynamic. deal. type in that MDI, characterize MDI. we were the MDI and our Now in type just we very the in actually want XX-XX X, growth. in is

strategically. that's smaller also and we in for of a market win our competitive lower Although switching, a part us emphasis

America. And your the of line with from Travis next of question comes Steed Bank

wanted questions. a the I things earlier of from to clarify couple

the did Jim, is can you you on decision year-over-year wanted to customer I year? And also disrupt naturally. clarify, grow good, were inventory So half you to commenting a grow the the say of starts made new second demand experience in but let and

in that? understand of the wanted So second you I make of a creates in really that to kind [indiscernible] outlook the So half? what

the say Travis, of we meant it the is I just what didn't customer said, disrupt to you want that opposite hope which I exact experience. way. don't I

times launch, going we as kind specialty actually entered the So the used it. pharmacy pharmacy, with specialty do Especially what's the we've approach way on pharmacy past. we a of upgraded in of that couple we've

-- time reimbursement brought launch. this this a code. with So to new of And is same the under compatibility kind that the Pod first channel same into with we've the the

we through time dynamic demand the we been base, by And through We're in it able important what would feather lot and specialty new clear right? So as because base, there it And pharmacies which of service out, through our that we've on built third-party was so customers pharmacy, are figuring to kind as it designing we And of The to in also what the allows on to starts the very And to should did hub well for taking I point take our first them new through up. is the pharmacies, to planned not focus strong grow how the because out into we're we've specialty most a into do. inventory customer customers to -- on most of base, it been that, new brings specialty GX has specialty of rather that saying pharmacies decided that, focus dynamic that pharmacy multiple be. great. to into really pharmacies. to And the the visible really data. it business us them were is a wasn't conversion than customer which actually and growing driving new our doesn't focusing market. us those set service

to there starts trying they So for customer be through able of GX IQVIA. are to new example, out watch starts, our other our see people most won't mechanisms, if reporting like

can So it. demand and is really flex we good, and so well flowing it's

that inventory And been experience and potentially for force into which decided would the for so customer we've retail partners to disruptive not has channel be customers. channel, our Therefore, great. both

inventory going transition very we're a retail let and well, It's going more So we're going specialty the natural at through pace. pharmacy. to in

is happy So why really and possible want how that's we experience, we're specialty strongest to going. deliver of it's because the pharmacy customer with new really customer,

on that question. that's So

yes, part year-over-year we expect I question, second second over the growth, it's is growth into the in hard call expectation get first of during year-over-year half year-over-year to your to But half. growth, the into when happens. cross exactly think On we that the

Michael from question next line with comes Wolfe Research. your the Polark And of

prioritize type expectation pricing? piece ask you question. And expand for this to the basal-only to interested the over the allow the and how this data follow-up the stage the then X product? And in to count process? through next that The on the the I a is, set second SECURE-TXD -- market that your type That's update. X I'll label back about MDI I'm half kind decision expect Would or one Okay. is to year, population? head heard will XX patient-agnostic both the to any launch to GO, for much of you way investments expect third pricing frame is you

Thanks for question. the Mike. Thanks,

would label, basal too us I intensive the label we get anticipate on both yes, the front users. to is, thing first far FDA to actual and want insulin insulin of The allow but to don't in the market

because up basal-only in So the were of that's had fantastic users, SECURE-TXD and SECURE-TXD the participants And backs aim. results. they XX% that

the better insulin to for bolus. the need fantastic X out because SmartAdjust you and on control goal -- adjusts and who adjusts who help of are is to as and it it ability so meal-time get algorithm there of know, Omnipod And people basal its both

I we think so want all in to know the for have and -- can don't basal-only take X. able goal. And patients of with if front of therefore, X, to it Contingent wide just patients we And we that's know just of expect, going range And we we're help it able initial to that people wait those to labeling, on can Omnipod Omnipod to than FDA that plan don't labeling, start X. and achieve that and -- you was needs we the going change, very as to to get that as to wait GO the Omnipod I insulin beauty get then strategy Omnipod to them to And of this meet. to needs caveats, wider their be were X don't and is on which on a the Omnipod we we have we people have meet Omnipod market X.

part So of forgotten second question. already your we're excited I've about the that. And

So...

the of company not impact. a operational longer-term simpler implications come to that about. our customer, that cycles, is wanted When with It's there. impact manufacturing that commented along and life capacity just No, much I the impact short-term that. of there's in in things have into terms those its all less and much fruits XXXX. going product operational the an things longer also with just talked Jim on just those think you a to the add a we it's that commercial, There all maybe comment of decision,

type we with but We'll covered, the There's add side scale well commercial people and reimbursed on distinction, more added about year. I force. anticipate sales is there's some now, the flagship pricing. other We so mean, the Yes, for sales we're on front. We'll say to for continue no don't that to your sales of other model actual then there. We'll changes able the expect already components, that to really earlier launch. of for been we've diabetes. get now -- platform have -- that adding on quickly that, excited the as to -- Omnipod Omnipod to see well closer X some right X happens, adding big in we the don't X with remember two Mike, heads what on been We as disruption. And go I about offer expect force being the force, any time. we we've successfully don't and

next with question comes line from the of your And Taylor Matt Jefferies.

and the of I shipping is terms the different further just talk color -- source the I about you Maybe of for of a and I did about talking could company, And lot been this mix of key about things And you guess in couple want could to mentioned clarify you in those? evolve? quarter. channels on could mix a as have some a you call. One ask as benefits and just channel help in the how outlook if that sand U.S. the get the I'm we've wondering

I'll Sure. one. with that start

at product end are we and have, And of So heavily end, the penetrated U.S., course, very and think of we pharmacy distributors in then the the now PBMs. the when wholesalers, ship we the the what customers. the it's is channel, we you and have

moves coverage. impact, in described some it is how into what dollars, to as is through That what we're go and but in not distributors all now So process. terms our should we that I have talking which pricing what relationships huge of with which call. And about PBMs specific hard what the with fluctuation we

will just and the into So channel. so a continue our it's continue But refine better to of better that. models now being we simple really dynamic around heavy to get and pharmacy

question Nephron. your from Chris with Pasquale And comes next

have math, International base a decision. had when U.S. share you are words, other the GO presence On your compete we geographies where I installed what OUS, curious International below for? how you and one on though, are is the able on one by our in well really percentage patients look at are those that much In you in that market, to of today? international where pie of overall I'm

Yes. Chris. Thanks,

Internationally, Nordics. larger Germany, XX And markets markets usual suspects large know, only OUS. U.K., as France, are markets, in we're the obviously the you of

in releases in of well. now the said the and we're -- X on -- we And think list out then And in really, Omnipod U.K. coming in France. just launches. And in growing opportunity. full the the France, the markets with are population, for the total X remarks, prepared then of is Omnipod and Nordics so you all gate we're Germany fairly as really similar with Med with launch can terms I Tech by just

which So where where another growth, as XXX And basis clearly it Omnipod we with what very we take to increase in out, roll winning It's good we're really we about on are bullish we X. us feel is point led guide. it.

comes line with Leerink Kratky question Mike of next your And the Partners. from

X launch. Maybe couple just a the on type

for you your change the today, pumps you on type population? X of once in launch commercial could Or population. full saw more basal-only the X? a approval? quick just updates be get And level based at maybe some provide does that on one a on in implement the to plan your is demand all basal-only can all, you sequence that of color launch? And the outlook But about that as a First then think you Omnipod

Thanks, Mike.

our FDA I full terms in launch, line we of expect of for what the terms done with mean, plan is what In in we've approval. we've launch comm choreographed

the on, to get channels we'll of we'll of be on year. feet so some But detail also our non-specialty FDA street. we markets. force in adding And with gives that. once that -- And like sales just by we the share approval expect to And also more reach place training say that. expanding closer the voice us anticipate, as into sales give said, able pieces anticipate terms more those with more as all end we I We into by we things and the have line so we'll other in promote and that in

get to later. And have being anticipate we so we'll that able to But promote we do as say about more clearance.

second question The of around... your side

Basal.

patient we how Basal, there with With GO thank looking in out Omnipod And product, were you. saw the we profiles. of patients basal, a channel. number present do at

with lot also profile channel. detail. we with won't a there was the diabetes a that And added patients insulin, what So to there's X of patient there. of I patient profiles We different went that profile we then in type draft X that that. to and patients a There's are try need in a in we -- patient found lot non-specialty type

of patients makes that So that lot us ability needs X we're with address I on about confident market. very to more Omnipod would can Omnipod to whose anything, X. bullish that say, there's -- And even penetrate we a our if focusing

really patients. are into those So there X kinds as we journey learned patient and those reach were a product as those taking in excited practices which lot the about there. happening what's about we're channels in for we the of to flagship in and Omnipod patients And

James. Bedford line question next of Jayson Raymond with your the And comes from

got clarifying questions. I'm kidding. XX I've just

more seeing in you X second, seem couple you X. at Xs. the X quickly Omnipod any benefit type timing you that the just -- for type of confident June? And presented Are late ADA in then Just type of data from approval

be in because clear, that adoption confident be place. a to in of is reimbursement? Just not going There's lag reimbursement to you're

thanks the and for Jayson, non-XX question list. Thanks,

mean, are so label X, request It's diabetes. I writing covered basis, and off not very So for that script it. of benefit. type for that's X on on that written -- reimbursed Omnipod right a well yes, physicians X confident. it's we're type that's for and very There's the is type which -- now through a X, pharmacy why Omnipod

full in indication X We type did the for see starts out lift MDI which X. for don't X. We Omnipod has that's see call We in user, DASH, patients in MDI an type increase for or the did whether Omnipod some quarter.

we said have promoting not for the do X their expansion diabetes And that. arm yet as have are indication back reps, to for X I've Omnipod will our us type that. use before, allow We one that behind do not for because tied

coverage we're that. But type There lift. really in should bullish Omnipod be X. any shouldn't the for And So fine. some coverage on in X delay we be have seen we think

And your with O'Brien the of line question next comes Sandler. Matthew from Piper

for the a that for important competitors, is the like just Secondly, for is how given clarifying to in starting are guys, inventory business? half I'd looks it's one. penetration type then it know first to to have guys I that. And durable this year? sorry, a the my how should on you tailwind so your going just MDI going between and what's forward do rates you accelerate, Is If you I type couple grow about the you results of be MDI question of as And of at side. driving look I'm the getting is second it new true? really technologies? What's love all, Xs Xs be your it it? main

Matt. Thanks,

tailwinds. So on I'll comment start with your inventory

the So all which that anticipate as reason we're is And we year, we come the GX saw And half that the talked channel through $XX the about second and should last the second managing transition quarter, what it million, we we process. were anticipating of happened quarter. a the destocking GX, during of during is around about how back.

Thanks, Matt.

the any type in think results. together On cobble say and reasonable I leading question. of I our won't I'll MDI clearly it's is X to competitors' MDI that. try to just that think penetration that accelerating, we're

very with X preferred patients. MDI is Omnipod So highly

to space conversions. we win that with grow to continue continue We and MDI

living road because of front very type and it's for the X effectively type some of burden in that very been our paving for CGM I because diabetes believe the both out I have X. reason time. And remains think durable with high partners us is and

back that to above that penetration we're CGM, penetration. And see very be a high, think in lot we of the kind space with X the on the well going and CGMs paved space the now go before we've you basis. ongoing that leader confident we can so, drives type adoption said type in road And that believe an of we're AID from that X XX% for of on the

the Dexcom, road see in to penetration to take a X type big in first-to-market paving space. likely opportunity X, our drive the Omnipod for so X are we a And that big of well. partners, there AID and Omnipod as and out us see opportunity and Abbott X as system We X type

Lichtman next the from your And comes Steve Oppenheimer. of with question line

international you're and you a On is it reimbursement are heading us can faster all to were you have internationally? And remind connectivity you better volume? the growth? versus strength the is seeing year, new thinking patient GX could it into you better when seeing pricing Or addition -- in

Thanks, Steve.

Yes.

sure this that done, our past, reimbursement in for system the the creates hard Omnipod launch for X we So patients. make what is commensurate referred and we've worked really Omnipod care and additional that to we've as with the health to we value X,

negotiate to, launched so Omnipod we've so And X, so a far, we've where premium it. been for good, successfully able

so it price is very where Omnipod -- for the are taken obviously, And are And us X -- a with very, it. benefit. we've volume both strong with bit but a good, and starts of volumes very, very

I'm second this question. again, of the then half And forgetting

The GX international.

GX, we announced timing. haven't

European into working We as working timing. So creating have for have it can, not it. in GX we a a the we're on us is big we'll as markets we but announced integration, get soon U.S., yet obviously which effective very tailwind obviously

question Wuensch the Joanne line And of comes from next with your Citibank.

this your of how agreement an or and the Abbott. by I and surprise, love doesn't people Very there was a landscape. lot took would I nice that changes change AID, opinion Yesterday, really think between announcement delivery the Medtronic quarter. on diabetes

Joanne. Thanks,

our X Yes, we're very CGM partners. happy with

We have a great Abbott. relationship with

in X X to year. great We're clear to And remain to for market We're expansions for sensor be. Plus map expansion of very includes X from ahead. We a extremely differentiated platform the speed We by have Omnipod have of really relationship and Omnipod that well working them. we and end with announce our both road continue us, full pumps it's confident X excited integration U.S. the bringing with competitive we'll a Libre Dexcom. position. the is the be that will very

very of And so ahead our with we're both speed full partners. bullish,

one be Bill for Canaccord Plovanic we question. last That with have Genuity. time will from And

good a quarter. on Congrats

In the that? benefits probably would much which gross was you product, from margin, GO, margin eliminating over assume. do And to then lower should profit gross how how shifting longer-term we a from up terms much by gross Malaysia, see potentially I of pick

curious that for of kind Just what GMs. the longer-term does

Great.

get that. Let started me on

So impact back out we of you have -- gross GO. we the strong commented, impact as the really once onetime margin

the We Malaysia to have first and for before be us. state, accretive. XX we strategic stated will is continue In years,

take moment, the that time. we're will at So ramping, so

you So and cycle. life around right at can product will be continue accretive the that expect point be. And to being that that other will the mark X-year

lines manufacturing time anticipate long-term guidance of providing things, away So here. that. taking We're we'll all from those shifting by and not

back we the clarify to page. of just here and up the color So come new starts early do the back we'll on on to and to in want more customer after come same questions wrap to some make take provide everybody XXXX. I sure opportunity is

a globally. third happen. The why is be growth, up lesser that customer And reiterate to year-over-year. of also about the so quarter, all that to there. we extent, working So to international but sequential true, on already question around third reasons quarter want would obvious because quarter fourth second came well, new only starts, And it's course, expect globally it's but to we quarter U.S., that to international, talked not I

NCS. contemplates U.S. in guidance growth Our year-over-year

I So for that was just everyone. sure that make to wanted clarified

question-and-answer gentlemen, And section. ladies and concludes our this

I Jim to conference Hollingshead for back would now like turn to Mr. remarks. the closing

Thank you, operator.

closing, excited In and with half. coming we're pleased very our our QX about second

iOS innovation of Omnipod Libre TAM clearance cascade the and we're GX for continues coming X Our type X U.S. and with FDA with anticipating to X. tailwind, eagerly expansion our and

the on strength continues to X. Our business of Omnipod outperform international

us to change amazing global possible our diabetes. be led none the that with board. of living Insulet across without guide morning that lives of And to our the All up of people raise would get who team every

to global us, for today. everybody, you, quarter. look thanks updating team. next you joining We And Thank forward

a we and thank conference, this you and you your Have concludes for wonderful all gentlemen, and ladies may day, today's disconnect. And participation.